Lundbeck's Latest Research Shows Significant Migraine Relief with Vyepti® in Real-World Settings New data from Lundbeck's INFUSE study demonstrates that Vyepti® leads to substantial improvements in migraine patients' conditions, presented at the HCOP Annual Conference.

Lundbeck's Latest Research Shows Significant Migraine Relief with Vyepti® in Real-World Settings #USA #Lundbeck #Ojai #Migraine #Vyepti

Lundbeck Seeks Approval for Vyepti® in Asian Countries to Treat Migraines Lundbeck has submitted a new drug application for Vyepti® in Japan, China, and South Korea, aiming to enhance treatment options for migraine sufferers.

Lundbeck Seeks Approval for Vyepti® in Asian Countries to Treat Migraines #Japan #Lundbeck #Valby #Vyepti #Eptinezumab

Lundbeck Posts 14% Revenue Growth on the Strength of Vyepti and Rexulti Lundbeck has reported a significant 14% growth in revenue for the first nine months of 2025, led by robust sales of Vyepti and Rexulti, fueled by strategic investments.

Lundbeck Posts 14% Revenue Growth on the Strength of Vyepti and Rexulti #Denmark #Lundbeck #Valby #Vyepti #Rexulti

Lundbeck Reports 14% Revenue Growth Driven by Key Strategic Medications Vyepti® and Rexulti® Lundbeck showcases impressive 14% revenue growth fueled by strategic investments in Vyepti® and Rexulti®. This article dives into the details of their financial performance and future outlook.

Lundbeck Reports 14% Revenue Growth Driven by Key Strategic Medications Vyepti® and Rexulti® #Denmark #Lundbeck #Valby #Vyepti #Rexulti

Migräne Antikörper Spritze zur subkutanen Selbstinjektion

Antikörper Game durchgespielt: Nach #Emgality, #Ajovy, #Vyepti und dem katastrophalen Versuch die #Migräne mit #Aquipta in den Griff zu kriegen, gibts jetzt #Aimovig. Hoffe das Zeug wirkt mal länger als ein Jahr.

Lundbeck Reveals New Migraine Clinical Data at IHC 2025: Eptinezumab Effects and More Lundbeck showcases significant migraine data at the 2025 International Headache Congress, highlighting the long-term effectiveness of Eptinezumab in chronic migraine patients, aiming to improve lives.

Lundbeck Reveals New Migraine Clinical Data at IHC 2025: Eptinezumab Effects and More #United_States #São_Paulo #Lundbeck #Vyepti #Eptinezumab

Lundbeck Unveils Groundbreaking Migraine Data at 2025 IHC, Highlighting Vyepti's Long-Term Effectiveness Lundbeck presents compelling data on Vyepti®'s long-term effectiveness in migraine prevention at the 2025 IHC, showcasing significant patient benefits.

Lundbeck Unveils Groundbreaking Migraine Data at 2025 IHC, Highlighting Vyepti's Long-Term Effectiveness #São_Paulo #Denmark #Lundbeck #Vyepti #Eptinezumab

New data suggests Vyepti offers hope for those with treatment-resistant migraines. Studies show significant reduction in migraine days for patients who previously found limited relief. A promising option for chronic sufferers. #migraine #Vyepti #neurol... Link

Vyepti® shows promise in Asia for chronic migraine sufferers! Clinical trials suggest it could significantly reduce monthly migraine days. A new option for those seeking relief. migraine #chronicmigraine #Vyepti #Asia #neurology #health #clinicaltrials Link

Eptinezumab Shows Significant Efficacy for Severe Migraine Patients in RESOLUTION Trial The phase IV RESOLUTION trial reveals that eptinezumab greatly reduces migraine days in patients with chronic migraine, providing new hope for severe migraine sufferers.

Eptinezumab Shows Significant Efficacy for Severe Migraine Patients in RESOLUTION Trial #Denmark #Valby #Vyepti #Eptinezumab #RESOLUTION_Trial

Eptinezumab Efficacy Confirmed in Asian Chronic Migraine Patients from Phase III Trial Results A recent trial shows that Eptinezumab effectively reduces monthly migraine days in the Asian population, crucial in addressing unmet healthcare needs.

Eptinezumab Efficacy Confirmed in Asian Chronic Migraine Patients from Phase III Trial Results #Denmark #Valby #Vyepti #Eptinezumab #SUNRISE_Trial

New Phase III Trial Results Showcase Efficacy of Vyepti® for Chronic Migraine in Asian Patients The latest findings from the SUNRISE trial reveal significant improvements in chronic migraine treatment efficacy for the Asian population using Vyepti® (eptinezumab).

New Phase III Trial Results Showcase Efficacy of Vyepti® for Chronic Migraine in Asian Patients #Denmark #Chronic_Migraine #Valby #Vyepti #Eptinezumab

How is Vyepti different from Aimovig? Official answer: Vyepti is different from Aimovig in that Vyepti is given as an infusion every 3 months whereas Aimovig is a...

Migraine Prevention: #Vyepti vs. #Aimovig
Vyepti:
IV infusion every 3 months
CGRP ligand antagonist

Aimovig:
Subcutaneous injection monthly
CGRP receptor antagonist

Both target CGRP to help prevent migraines.

How is Vyepti different from Aimovig? Official answer: Vyepti is different from Aimovig in that Vyepti is given as an infusion every 3 months whereas Aimovig is a...

Struggling with Migraines? #Vyepti and #Aimovig are two options that work by targeting CGRP, a key factor in migraines.
🔹 Vyepti: Given as an IV infusion once every 3 months.
🔹 Aimovig: A self-administered injection once a month.
Both help reduce the frequency of migraines.

Got ~2 weeks of #Migraine relief. Not sure if it’s from the #Vyepti, the L-side cervical #Ablation, the pre-op ketamine, or some combo. 🤔

Alas, my luck’s finally run out, so I’m trying out my new frozen head wrap. 🤕

This is a mini look at life with #ChronicIllness. Raw, unshowered, & unfiltered. 😖

Day 1, post-1st #Vyepti treatment.

No reaction during the infusion last night. 👍

But I still had to take emergency #Migraine meds this morning. 😔

I’m REALLY trying not to feel discouraged, but…

*siggghhhh*

Second dose of Vyepti today… here’s to hoping it helps reduce my migraines 🤯 #migraines #IV #vyepti